Clinical Trial Search

Primary: Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) — -6.0; -6.1 score on a scale — p=0.944

Primary: Feasibility Measure: Enrollment (Young Adult Survivors) - Number of Eligible Patients Consented and Completing Baseline — 50; 29 Participants

Primary: Difference in Resting CTTI Between Carvedilol CR (Beta-blocker) and Valsartan (ARB) in Combination With Lisinopril. — 2447; 2500 CTTI units (mmHg*beats/min) — p=<0.05

Primary: Immune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake — 60.53; 60; 59.29; 56.52 percentage of cells

Primary: Resting Energy Expenditure After 12 Weeks of Drug Therapy (kcal/Day) — 1267; 1268 kcal/day

Primary: Change From Baseline to 11 Months in Maximum Consumption of Oxygen (mlO2/kg/Min) Using Cardiopulmonary Exercise Testing (CPET) — 0.05; 0.08 ml O2/min/kg — p=0.5858

Primary: Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From Baseline — 7; 6 Participants

Primary: Change in Gait Velocity — 0.28; 0.04 meters per second — p=0.071

Primary: Abstinence — 55.0; 49.5 days

Primary: Percent Change From Baseline in Maximum Reading Speed of Oculus Unitas (OU) (Both Eyes) at Week 48, as Measured Using the Minnesota Low Vision Reading Test (MNREAD)…

Primary: Safety: AEs, SAEs, ADEs, SADEs, UADEs — 0; 0; 0; 0 Events

Primary: Plasma Glucose Levels in Response to Mixed Meal Testing - Area Under the Curve for Plasma Glucose — 2828; 2893 mg*min/dL — p=0.90

Primary: Part 1: Change From Baseline in Symptom Assessment in Dry Eye (SANDE) Score — -6.0; -8.1; -4.9; -1.8 Score on scale — p=0.585

Primary: Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26 — -3.1; -1.4 units on a scale — p==0.0009

Primary: Objective Response Rate (ORR) — 64 percentage of participants